Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Genomma Lab InternacionalB de CV's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.35.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Genomma Lab InternacionalB de CVcouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Cash-to-Debt or its related term are showing as below:
MEX:LABB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 0.24 Max: 0.41
Current: 0.35
During the past 13 years, Genomma Lab InternacionalB de CV's highest Cash to Debt Ratio was 0.41. The lowest was 0.15. And the median was 0.24.
MEX:LABB's Cash-to-Debt is ranked worse than 67.75% of 986
companies
in the Drug Manufacturers industry
Industry Median: 1.005
vs MEX:LABB: 0.35
Genomma Lab InternacionalB de CV (MEX:LABB) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Genomma Lab InternacionalB de CV Cash-to-Debt Related Terms
Genomma Lab InternacionalB de CV Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Genomma Lab InternacionalB de CV Cash-to-Debt Chart
MEX:LABB vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Cash-to-Debt of 0.35 as of Mar. 2026. This is 46% above median its historical median of 0.24. Over the past decade, Genomma Lab InternacionalB de CV's Cash-to-Debt has ranged from 0.15 to 0.41. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #668 out of 986 companies in the Drug Manufacturers industry, placing it in the top 67.7%.
Is Genomma Lab InternacionalB de CV's Cash-to-Debt too high?
Genomma Lab InternacionalB de CV's current Cash-to-Debt of 0.35 is 46% above median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.41. The Drug Manufacturers industry median Cash-to-Debt is 1.01. Genomma Lab InternacionalB de CV's value of 0.35 is 65.2% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #668 out of 986 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #668 out of 986 companies for Cash-to-Debt. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Cash-to-Debt is 1.01. Genomma Lab InternacionalB de CV's value of 0.35 is 65.2% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Cash-to-Debt has ranged from 0.15 to 0.41 over the past decade. While the company's 10-year median is 0.24 vs. the industry median of 1.01, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.01, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Cash-to-Debt of 0.35 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Cash-to-Debt is 0.35, which is 46% above median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.70, compared to a current price of MXN14.73 — trading 16.8% below its estimated fair value. The current Cash-to-Debt is 0.35, which is 46% above median its 10-year median of 0.24 and 65.2% below the Drug Manufacturers industry median of 1.01. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Cash-to-Debt is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.73 is trading 16.8% below its estimated GF Value™ of MXN17.70.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Cash-to-Debt: 0.35 (46% above median its 10-year median of 0.24)
GF Value™: MXN17.70 vs. price of MXN14.73 (16.8% below fair value)
Industry Position: 65.2% below the Drug Manufacturers median (#668 of 986)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
